Posted by SLS on August 31, 2001, at 11:52:24
In reply to Re: Edronax - had it ! » JohnL, posted by SLS on August 31, 2001, at 7:04:00
For anyone who doesn't have the Adobe Acrobat Reader to view the link I provided in my previous post, here is a text version:
http://home.att.net/~sl.schofield/medical/adrafinil_modafinil.htm
Here is some additional manufacturer information:Adrafinil (Olmifon)
Laboratoire L. LAFON
Laboratoire Louis Lafon
Siège
19, avenue du Pr Cadiot
94701 MAISONS-ALFORT
Tél : 01.49.81.81.00
France country code: 33
www.lablafon.com
LAFON
Adresse : 20, rue Charles Martigny
BP22
94701 MAISONS ALFORT
Telephone : 01.49.81.81.00
Telecopie : 01.48.98.13.72
France country code: 33
The Adobe Acrobat Reader is a free program to be used to view files in Adobe PDF format. It functions as a stand-alone viewer and integrates with your browser to view files on-line. You can download a copy of the Acrobat Reader from this web page:http://www.adobe.com/products/acrobat/readstep2.html
Or download directly by clicking on this link:
ftp://ftp.adobe.com/pub/adobe/acrobatreader/win/5.x/ar500enu.exe
>
> Dear JohnL,
>
> Regarding pharmacodynamics, I have found that even manufacturer's labels and package inserts can be wrong, especially early in a drug's life. Modafinil (Provigil), the immediate metabolite of adrafinil, is a good expample. After being marketed in the US for awhile, they updated their package label from claiming it was a NE alpha-1 agonist to stating that they didn't know what the hell the drug did. Of course, they used nicer words.
>
> The following is an excerpt from a recent Cephalon package insert for Provigil (modafinil). The insert is copyrighted 1999. It details the reasons why it has been concluded that Provigil does NOT bind to and stimulate NE alpha-1 receptors.
>
> "Modafinil does not appear to be a direct or indirect alpha-1 adrenergic agonist. Although modafinil-induced wakefulness can be attenuated by the alpha-1 adrenergic receptor antagonist, prazosin, in assay systems known to be responosive to alpha-adrenergic agonists, modafinil has no activity. Modafinil does not display sympathomimetic activity in the rat vas deferens preparations (agonist-stimulated or electrically stimulated) nor does it increase formation of the adrenergic-mediated second messenger phosphatidyl inositol in in vitro models. Unlike sympathomimetic agents, modafinil does not reduce cataplexy in narcoleptic canines and has minimal effects on cardiovascular and hemodynamic parameters."
>
> You can compare this with:
>
> http://www.smart-drugs.com/ias-Modafinil.htm
>
> Then, you can look at this:
>
> http://www.nevapress.com/cnsdr/full/5/3/193.pdf
>
> "The literature on modafinil, the primary metabolite of adrafinil is much more ex- tensive. This work has largely focused on the potential application of modafinil in the treatment of sleep disorders, and modafinil has recently received regulatory approval for the treatment of narcolepsy in the United States. Since the types of clinical trials that have been conducted differ (vigilance enhancement for adrafinil vs. narcolepsy for modafinil), it is not clear whether modafinil effectively replaces adrafinil or whether the two com- pounds are uniquely valuable for different applications. Most investigators assume that adrafinil and modafinil both serve as 1-adrenergicreceptor agonists. The evidence in support of this hypothesis, however, is weak, and other mechanisms of action are probable. This review focuses primarily on adrafinil, but it also reviews studies on modafinil that help to clarify the underlying mechanisms of action of adrafinil. This review also considers potential novel applications of adrafinil in the treatment of disorders associated with dementia."
>
> Please let me know if there is anything else I can help you with.
>
>
> - Scott
poster:SLS
thread:76755
URL: http://www.dr-bob.org/babble/20010828/msgs/77073.html